ABOUT AIMx PODIATRY AND THE PODIATRIC INDUSTRY

The most common reason podiatrists hesitate to offer cash-pay regenerative treatments is not product confidence. It is the conversation. Nobody wants to feel like they are selling to a patient. Here is how to reframe it. The Conversation Most Podiatrists DreadYou have just finished explaining a treatment option to a patient, one you genuinely believe […]

Insurance reimbursements are shrinking. Administrative burden is growing. And patients are increasingly willing to pay out of pocket for treatments that actually work. Cash-pay podiatry is not a trend. It is a structural shift. Here is how to position your practice to benefit from it.

Millions of people walk around every day with chronic foot pain that nobody has been able to fully explain, let alone fix. For a significant portion of them, the answer is fat pad atrophy. And most of them have never heard of it.